| 10629ETCTN |
A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with
Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients
with Extensive-Stage Small Cell Lung Cancer |
Open |
| 1563GCC |
Mitigation of radiation pneumonitis and fibrosis |
Open (affiliates only) |
| 1950GCCC |
First in Human Phase 1A (dose escalation) and I B (expansion cohorts) Study of [IND
# Agent-AG01 a Chimeric Monoclonal Antibody against Glycoprotein GP88] in advanced
Solid Tumor Malignancies (1A) with expansion cohorts (1B) in advanced Triple Negative
Breast Cancer, Hormone Resistant Breast Cancer, advanced Non-small Cell Lung Cancer
(NSCLCA) and advanced Mesothelioma |
Open |
| 2230GCCC |
BT012:A randomized pivotal study assessing the efficacy of targeted blood-brain barrier
(BBB) disruption using Exablate focused ultrasound during the standard of care treatment
of brain metastases of non-small cell lung cancer (NSCLC) origin |
Open |
| 2421GCCC |
A phase 2 study of alisertib in patients with extensive stage small cell lung cancer
|
Open |
| 2441GCCC |
Tempus GEMINI NSCLC Study: A Longitudinal Multi-Omic Biomarker Profiling Study of
Patients with Non-Small Cell Lung Cancer (NSCLC) |
Open |
| 2449GCCC |
GCCC:2449 Signature Development and Validation Protocol for an Epigenetic Assay in
Diagnosing Lung Cancer |
Open |
| 2468GCCC |
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd),
a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC)
in Subjects with Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02) |
Open |
| 2497GCCC |
A Phase 1 Single-Arm Single-Institution Study Evaluating Neoadjuvant Chemoimmunotherapy
with Immuno-sensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
(NeoRADjuvant Trial) |
Open |
| 25103GCCC |
Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line
Treatment of Extensive-Stage Small Cell Lung Cancer |
Open |
| 2538GCCC-M |
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations
in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR) |
Open |
| 2538GCCC-S2 |
Sub-study 2: Rilvegostomig in Combination with Standard of Care Chemotherapy
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations
in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR) |
Open |
| 2543GCCC |
University of Maryland Greenebaum Comprehensive Cancer Center Lung Cancer Prevention
Program |
Open |
| 2544GCCC |
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy
and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants
with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02 |
Open |
| 2567GCCC |
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or
Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous
Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) |
Open |
| 2574GCCC |
Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers in Response
to Pembrolizumab with or without Chemotherapy in Black Patients with NSCLC |
Open |
| 2583GCCC |
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics,
and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell
Lung Cancer - The ONKORAS-101 Study |
Open |
| 2620GCCC |
Evaluation of the accuracy of potential doubling time of the tumor (Tpot) using target
volumes with
CBCT in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
|
Open |
| 2627GCCC |
A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in
combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin,
and etoposide as first-line treatment in patients with extensive-stage small cell
lung cancer (DAREON®-Lung-1) |
Open |
| A081801 |
Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO |
Open |
| A172401 |
Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits
and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated
in Community Oncology Clinics / WF2304-A172401 |
Open |
| EA5221 |
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the
Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study |
Open |
| NRG-CC009 |
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant
Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell
Lung Cancer
|
Open (affiliates only) |
| S2409 |
PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating
maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage
Small Cell Lung Cancer (ES-SCLC) |
Open |